Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma

Background:Despite the recent improvements in multimodal therapies for oesophageal squamous cell carcinoma (ESCC), the prognosis remains poor. The identification of suitable biomarkers for predicting the prognosis and chemo-sensitivity is required to develop targeted treatments and improve treatment results.Methods:Proteins highly expressed in ESCC cell lines compared with normal oesophageal cell lines were screened by isobaric tag for relative and absolute quantitation (iTRAQ). We identified glypican-1 (GPC1) as a novel molecule. The clinicopathological characteristics of GPC1 were evaluated by immunohistochemistry using ESCC specimens, and clinical parameters were assessed. The correlation between GPC1 expression levels and chemo-sensitivity were analysed in vitro.Results:In the immunohistochemical assessment of 175 ESCC patients, 98.8% expressed GPC1. These patients demonstrated significantly poorer prognosis compared with patients with low-GPC1 expression by survival assay (P<0.001). Higher chemoresistance was observed in the GPC1 high-expression group. GPC1 expression levels positively correlated with chemo-sensitivity against cis-Diammineplatinum (II) dichloride (CDDP), and are potentially associated with anti-apoptotic function based on alterations in the MAPK downstream signalling pathway and Bcl-2 family member proteins.Conclusions:GPC1 is an independent prognostic factor in ESCC and is a critical molecule for altering the threshold of chemoresistance to CDDP.

• Publication year

  2016

• Venue

  British Journal of Cancer

• Publication date

  2016-06-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bjc.2016.183PMID 27310703PMCID 4931380
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer.

  2017cited by this paper
• Glypican-1 stimulates Skp2 autoinduction loop and G1/S transition in endothelial cells.

  2016cited by this paper
• The history of lymphadenectomy for esophageal cancer and the future prospects for esophageal cancer surgery

  2015cited by this paper
• Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Leucine-rich α-2-glycoprotein promotes TGFβ1-mediated growth suppression in the Lewis lung carcinoma cell lines

  2015cited by this paper
• Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis

  2015cited by this paper
• Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy

  2015influential reference
• Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

  2015cited by this paper
• Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy

  2014influential reference
• Heparan Sulfate Proteoglycans and Human Breast Cancer Epithelial Cell Tumorigenicity

  2014cited by this paper
• EpCAM, a Potential Therapeutic Target for Esophageal Squamous Cell Carcinoma

  2014cited by this paper
• Controls for Immunohistochemistry

  2014cited by this paper
• Novel Strategy for Biofilm Inhibition by Using Small Molecules Targeting Molecular Chaperone DnaK

  2014cited by this paper
• Esophageal carcinoma.

  2014cited by this paper
• Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer

  2013cited by this paper
• Glypican 1 Stimulates S Phase Entry and DNA Replication in Human Glioma Cells and Normal Astrocytes

  2013cited by this paper
• Oesophageal carcinoma.

  2013cited by this paper
• Molecular mechanisms of cisplatin resistance

  2012cited by this paper
• Antiproliferative effect of SOCS‐1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells

  2012cited by this paper
• The structural role of N-linked glycans on human glypican-1.

  2011cited by this paper
• Glypican-1 Stimulates Skp2 Autoinduction Loop and G1/S Transition in Endothelial Cells

  2011cited by this paper
• Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications

  2011cited by this paper
• Japanese classification of gastric carcinoma: 3rd English edition

  2011cited by this paper
• Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88.

  2010cited by this paper
• S-Nitrosylation of secreted recombinant human glypican-1

  2009cited by this paper
• Constitutive Overexpression of P-glycoprotein, Rather than Breast Cancer Resistance Protein or Organic Cation Transporter 1, Contributes to Acquisition of Imatinib-Resistance in K562 Cells

  2008cited by this paper
• Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells.

  2008cited by this paper
• Glypican-1 regulates anaphase promoting complex/cyclosome substrates and cell cycle progression in endothelial cells.

  2008cited by this paper
• Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells.

  2006cited by this paper
• Growth factor–induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells

  2005cited by this paper
• Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S

  2004cited by this paper
• Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145.

  2004cited by this paper
• Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.

  2001cited by this paper
• Glypican-1 Is a VEGF165 Binding Proteoglycan That Acts as an Extracellular Chaperone for VEGF165 *

  1999cited by this paper
• Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells.

  1999cited by this paper
• The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer.

  1998cited by this paper
• Japanese classification of gastric carcinoma

  1995cited by this paper

• Overexpression of Transferrin Receptor in Esophageal Squamous Cell Cancer Suggests Poor Prognosis and Potential Therapy

  2025cites this paper
• Deciphering Cancer Complexity: Integrative Proteogenomics and Proteomics Approaches for Biomarker Discovery.

  2025cites this paper
• Current and Emerging Fluorescence-Guided Techniques in Glioma to Enhance Resection

  2025cites this paper
• Update Nuklearmedizin 2025: Theranostik

  2025cites this paper
• Assessing efficacy of anti-glypican-1 antibody–drug conjugate as potential therapeutic approach for gastric cancer

  2025cites this paper
• Co-therapy with S1P and heparan sulfate derivatives to restore endothelial glycocalyx and combat pro-atherosclerotic endothelial dysfunction.

  2025cites this paper
• Diagnostic value of glypican-1; a new marker differentiating pulmonary squamous cell carcinoma from adenocarcinoma: immunohistochemical study on Egyptian series

  2025cites this paper
• Diagnostic and prognostic value of circulating exosomal glypican-1 in pancreatic cancer: a meta-analysis.

  2024cites this paper
• Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges.

  2024cites this paper
• Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancer

  2024cites this paper
• Glypican-1-targeted antibody–drug conjugate inhibits the growth of glypican-1-positive glioblastoma

  2024influential citation
• Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior

  2023cites this paper
• Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• Silencing Glypican-1 enhances the antitumor effects of Pictilisib via downregulating PI3K/Akt/ERK signaling in chemo-resistant esophageal adenocarcinoma

  2023cites this paper
• Targeting Glypican-1 Reverses Resistance to 5-Fluorouracil in Esophageal Adenocarcinoma Cells

  2023cites this paper
• Nano-particulate Toll-like Receptor 9 Agonist Potentiates the Antitumor Activity of Anti-Glypican-1 Antibody

  2023cites this paper
• Pharmacokinetics and Biodistribution of 89Zr-Miltuximab and Its Antibody Fragments as Glypican-1 Targeting Immuno-PET Agents in Glioblastoma.

  2023cites this paper
• GPC2 deficiency inhibits cell growth and metastasis in colon adenocarcinoma

  2022cites this paper
• Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma

  2022cites this paper
• GPC1 Is Associated with Poor Prognosis and Treg Infiltration in Colon Adenocarcinoma

  2022cites this paper
• The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• Hyperphagia in offsprings of in utero hyperglycemic mothers is associated with increased expression of heparan sulfate proteoglycans in hypothalamus

  2022cites this paper
• Clinical development of an anti-GPC-1 antibody for the treatment of cancer

  2022cites this paper
• Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers.

  2021cites this paper
• New kid on the block in theranostics: Glypican-3

  2021cites this paper
• Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management

  2021cites this paper
• A guide to the composition and functions of the extracellular matrix

  2021cites this paper
• Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung

  2021cites this paper
• Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients

  2021cites this paper
• Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer

  2021cites this paper
• Development of Molecules Antagonizing Heparan Sulfate Proteoglycans

  2021cites this paper
• Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers

  2021cites this paper
• Identification and validation of a hypoxia-related prognostic and immune microenvironment signature in bladder cancer

  2021cites this paper
• CD70 antibody‐drug conjugate: A potential novel therapeutic agent for ovarian cancer

  2021cites this paper
• Evaluation of antitumor potential of an anti-glypican-1 monoclonal antibody in preclinical lung cancer models reveals a distinct mechanism of action

  2021cites this paper
• Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma

  2021cites this paper
• A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma

  2021cites this paper
• Glypican-1 Overexpression in Different Types of Breast Cancers

  2021cites this paper
• Proteoglycans and their functions in esophageal squamous cell carcinoma

  2021cites this paper
• The Role of Glypican-1 in Regulating Multiple Cellular Signaling Pathways.

  2021cites this paper
• Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody–Drug Conjugates in Pancreatic Cancer

  2021cites this paper
• Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target

  2021cites this paper
• Cytl1 is a Key Target for Chemoradiotherapy Resistance in Locally Advanced Cervical Cancer: Based on Bioinformatics Analysis

  2021cites this paper
• Molecular Profile Study of Extracellular Vesicles for the Identification of Useful Small “Hit” in Cancer Diagnosis

  2021cites this paper
• Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer

  2020cites this paper
• Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma

  2020cites this paper
• Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms

  2020cites this paper
• A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells

  2020cites this paper
• The feasibility of Miltuximab®-IRDye700DX-mediated photoimmunotherapy of solid tumors.

  2020cites this paper
• A glycolysis-related gene pairs signature predicts prognosis in patients with hepatocellular carcinoma

  2020cites this paper
• The Glycocalyx and Its Role in Vascular Physiology and Vascular Related Diseases

  2020cites this paper
• High glypican-1 expression is a prognostic factor for predicting a poor clinical prognosis in patients with hepatocellular carcinoma

  2020cites this paper
• Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids.

  2020cites this paper
• Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression

  2020cites this paper
• The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers

  2020cites this paper
• The Glycocalyx core protein Glypican 1 protects vessel wall endothelial cells from stiffness-mediated dysfunction and disease.

  2020cites this paper
• The Role of Glypicans in Cancer Progression and Therapy

  2020cites this paper
• The Proteomic Analysis of Exosomes from Breast Cell Lines Reveals Potential Biomarkers of Breast Cancer

  2020cites this paper
• Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

  2020cites this paper
• Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab®-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery

  2020cites this paper
• The Role of Glypican-1 in the Tumour Microenvironment.

  2020cites this paper
• Tumor Microenvironment: Extracellular Matrix Components – Part A

  2020cites this paper
• GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab

  2020cites this paper
• Glypican-1 in human glioblastoma: implications in tumorigenesis and chemotherapy

  2020cites this paper
• Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells

  2019cites this paper
• Glypican-1 Promotes Tumorigenesis by Regulating the PTEN/Akt/β-Catenin Signaling Pathway in Esophageal Squamous Cell Carcinoma

  2019cites this paper
• The cancer cell glycocalyx proteoglycan Glypican-1 mediates interstitial flow mechanotransduction to enhance cell migration and metastasis

  2019cites this paper
• The Glypican-4 Gene Polymorphism rs1048369 and Susceptibility to Epstein-Barr Virus-Positive and -Negative Nasopharyngeal Carcinoma in Northern China

  2019cites this paper
• The Expression, Regulation, and Biomarker Potential of Glypican-1 in Cancer

  2019cites this paper
• Role of Glypicans in Regulation of the Tumor Microenvironment and Cancer Progression.

  2019cites this paper
• Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment

  2018cites this paper
• Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer

  2018cites this paper
• Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics.

  2018cites this paper
• High levels of serum glypican‐1 indicate poor prognosis in pancreatic ductal adenocarcinoma

  2018cites this paper
• Glypicans as Cancer Therapeutic Targets.

  2018cites this paper
• Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity

  2018cites this paper
• Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer

  2018cites this paper
• Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma

  2018cites this paper
• Multiple antibodies identify glypican-1 associated with exosomes from pancreatic cancer cells and serum from patients with pancreatic cancer

  2018cites this paper
• Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma

  2018cites this paper
• Elevated glypican‐1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma

  2017cites this paper
• Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma

  2017cites this paper
• Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance.

  2017cites this paper
• Proteoglycans remodeling in cancer: Underlying molecular mechanisms.

  2017cites this paper
• Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma

  2017cites this paper
• High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas.

  2017cites this paper
• Multiple antibodies identify Glypican-1 on serum exosomes from patients with pancreatic cancer

  2017cites this paper
• Development of an Anti-Glypican-1 Monoclonal Antibody G1Mab-28 for Flow Cytometry, Western Blotting, and Immunohistochemistry

  year unknowncites this paper
• Die Onkologie

  year unknowncites this paper